D
Daniele Santini
Researcher at Università Campus Bio-Medico
Publications - 742
Citations - 23795
Daniele Santini is an academic researcher from Università Campus Bio-Medico. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 64, co-authored 684 publications receiving 19958 citations. Previous affiliations of Daniele Santini include Seconda Università degli Studi di Napoli & University of Pisa.
Papers
More filters
Journal ArticleDOI
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso,Miriam Martini,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi,Josep Tabernero,Teresa Macarulla,Frédéric Di Fiore,Alice Gangloff,Fortunato Ciardiello,Per Pfeiffer,Camilla Qvortrup,Tine Plato Hansen,Eric Van Cutsem,Hubert Piessevaux,Diether Lambrechts,Mauro Delorenzi,Mauro Delorenzi,Sabine Tejpar +37 more
TL;DR: This is the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era and confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA population response rates confirmed that.
Journal ArticleDOI
Management of cancer pain: ESMO Clinical Practice Guidelines
TL;DR: Supportive Care in Cancer Unit, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy ; Oncologia Medica, Università Campus Bio-Medico, Rome, Italy; Department of Oncology, Radiation Oncologists Centre, S. Maria Hospital, Terni, Italy.
Journal ArticleDOI
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
Fotios Loupakis,Annamaria Ruzzo,Chiara Cremolini,Bruno Vincenzi,Lisa Salvatore,Daniele Santini,Gianluca Masi,I. Stasi,Emanuele Canestrari,Eliana Rulli,Irene Floriani,Katia Bencardino,N Galluccio,Vincenzo Catalano,Giuseppe Tonini,Mauro Magnani,Gabriella Fontanini,Fulvio Basolo,Alfredo Falcone,Francesco Graziano +19 more
TL;DR: Assessing KRAS codons 61/146 and BRAF V600E mutations might help optimising the selection of the candidate patients to receive anti-EGFR moAbs in metastatic colorectal cancer.
Journal ArticleDOI
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis,Luca Pollina,I. Stasi,Annamaria Ruzzo,Mario Scartozzi,Daniele Santini,Gianluca Masi,Francesco Graziano,Chiara Cremolini,Eliana Rulli,Emanuele Canestrari,Niccola Funel,Gaia Schiavon,Iacopo Petrini,Mauro Magnani,Giuseppe Tonini,Daniela Campani,Irene Floriani,Stefano Cascinu,Alfredo Falcone +19 more
TL;DR: PTEN loss in metastases may be predictive of resistance to cetuximab plus irinotecan and the combination of PTEN IHC and KRAS mutational analyses could help to identify a subgroup of patients with mCRC who have higher chances of benefiting from EGFR inhibition.
Journal ArticleDOI
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Wen Guo Jiang,Andrew James Sanders,Masaru Katoh,H. Ungefroren,Frank Gieseler,Mark E. Prince,Sarah K. Thompson,Massimo Zollo,Daniela Spano,P. Dhawan,Daniel Sliva,Pochi R. Subbarayan,Malancha Sarkar,Kanya Honoki,Hiromasa Fujii,Alexandros G. Georgakilas,Amedeo Amedei,Elena Niccolai,Amr Amin,S. Salman Ashraf,Lin Ye,William G. Helferich,Xujuan Yang,Chandra S. Boosani,Gunjan Guha,Maria Rosa Ciriolo,Katia Aquilano,Sophie Chen,Asfar S. Azmi,W N Keith,Alan Bilsland,Dipita Bhakta,Dorota Halicka,Somaira Nowsheen,Francesco Pantano,Daniele Santini +35 more
TL;DR: This review lists the disruption of E-cadherin and tight junctions, key signaling pathways, including urokinase type plasminogen activator (uPA), phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene (PI3K/AKT), focal adhesion kinase (FAK), β-catenin/zinc finger E-box binding homeobox 1 (ZEB